The global Ovarian Cancer Drugs Market Growth Accelerated by Increasing Spending on Targeted Therapies



Ovarian cancer drugs are used for the treatment of ovarian cancer, which is becoming one of the leading cause of cancer related deaths among women. Ovarian cancer drugs help in fighting cancer by slowing down or stopping the growth and spread of cancer cells in the body. Targeted therapies have shown promising results with minimal side effects and are much more effective than traditional chemotherapy drugs for ovarian cancer treatment.

The global Ovarian Cancer Drugs Market is estimated to be valued at US$ 4.2 billion in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends that is driving the growth of the ovarian cancer drugs market is increasing spending on targeted therapies. Targeted therapies that attack specific vulnerabilities within cancer cells have gained significant prominence over the recent past. For example, PARP inhibitors prevent DNA damage repair in cancer cells with BRCA gene mutations and have shown robust clinical activity against ovarian cancer. Increased R&D funding from pharmaceutical companies and governments in developing innovative targeted therapies is fueling the ovarian cancer drugs market growth. Several targeted drug candidates are currently under clinical trials that can potentially get approved and offer new treatment options for women suffering from ovarian cancer.


Segment Analysis

The global ovarian cancer drugs market is dominated by platinum based drugs segment. Platinum based drugs such as carboplatin and cisplatin, either used alone or in combination with other drugs like paclitaxel, are one of the first line treatment options for ovarian cancer patients. They have emerged as standard chemotherapy regimens for ovarian cancer due to their high efficacy. Monotherapy remains the most prescribed treatment, however, combination therapy provides better outcomes and is becoming more popular.

Key Takeaways

The global Ovarian Cancer Drugs Market is estimated to be valued at US$ 4.2 billion in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030.

Regional analysis: North America accounted for the largest share of the ovarian cancer drugs market in 2022. This is attributed to the rising incidence of ovarian cancer and advanced healthcare infrastructure in the region enabling access to innovative and costly treatments. Asia Pacific is expected to witness the highest growth during the forecast period due to improving access to modern cancer therapies in developing countries.

Key players: Key players operating in the ovarian cancer drugs market are GlaxoSmithKline, Allergan, AstraZeneca, Pfizer, and Roche. GSK emerged as the leader in the global ovarian cancer drugs market, primarily due to its strong portfolio of pipeline molecules and marketed drugs such as Zejula and Arzerra for ovarian cancer. Allergan secured the second position owing to strong sales of its blockbuster drugs Namenda and Botox. AstraZeneca captured the third position and is engaged in developing novel targeted therapies for ovarian cancer.

Comments

Post a Comment

Popular posts from this blog

Neuroendocrine Cancer is the fastest growing segment fueling the growth of Pituitary Cancer Market

Image
The pituitary cancer market comprises of medical treatment options for patients diagnosed with pituitary cancer. Pituitary cancers are rare tumors that start in the pituitary gland which is a pea-sized gland located at the base of the brain.  The global Pituitary Cancer Market is estimated to be valued at US$ 380.7 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.    Market key trends: One of the key trends fueling the growth of the pituitary cancer market is rising preference of targeted drug therapy over conventional chemotherapy. Targeted drug therapies mainly include somatostatin analogs and dopamine agonists which directly act on cancer cells and have less side effects compared to chemotherapy. These targeted drugs are effective in controlling symptoms and slowing tumor growth in patients with hormone secreting pituitary adenomas and carcinomas. The targe...
Read more

Enhancing Patient Care and Comfort: The Evolution of Hospital Beds

Image
  Hospital beds play a crucial role in patient care, providing comfort, safety, and functionality for individuals requiring medical attention. Over the years, advancements in technology and design have revolutionized hospital beds, leading to improved patient outcomes and caregiver efficiency. From basic adjustable beds to sophisticated models equipped with cutting-edge features, the evolution of hospital beds has transformed the healthcare landscape. Evolution of Hospital Beds: Historically, hospital beds were simple in design, primarily consisting of a metal frame with adjustable height and manual controls. However, as medical practices advanced and patient needs became more complex, the demand for more versatile and ergonomic hospital beds grew. In recent decades, significant strides have been made in the development of hospital bed technology. Modern hospital beds are designed with a focus on patient comfort, safety, and mobility. Features such as electronic controls, motorize...
Read more

Dry Eye Disease Market is Estimated to Witness High Growth Owing to Rising Awareness About Disease Management

Image
  Dry eye disease, also known as keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by lack of sufficient moisture and tear film instability. Common symptoms of dry eye include stingy or burning sensation in eyes and blurred vision.   Market Dynamics : The Dry Eye Disease Market is witnessing high growth owing to rising awareness about disease management and increasing number of people experiencing symptoms of dry eyes. According to the report, increasing usage of electronic devices and prolonged screen time is a major driver fueling the demand for dry eye treatments. Additionally, growing geriatric population worldwide who are more prone to dry eyes is also contributing to the market growth. Availability of various treatment options along with new product launches is further expected to boost the market during forecast period.   Increasing Prevalence of Dry Eye Disease is Driving Market Growth   One of the major market drive...
Read more